ERBB2 and breast carcinoma: While rare, we noticed clinically significant mutations in CDKN2A, which belongs to the cell cycle pathway, in the HER2+ subtype of breast cancer (P < 0.05), indicating the potential benefit of CDK4/6 inhibitors.